Literature DB >> 15197535

Direct interference of HIV protease inhibitors with pancreatic beta-cell function.

M Düfer1, Y Neye, P Krippeit-Drews, G Drews.   

Abstract

The aim of the present study was to evaluate whether HIV protease inhibitors directly interfere with stimulus-secretion coupling in pancreatic beta-cells. Insulin secretion was determined by a radioimmunoassay (RIA), cytosolic free Ca2+ concentration ([Ca2+]c) with the fluorescence dye fura-2 and whole-cell membrane currents with the patch-clamp technique. Glucose-induced insulin secretion was inhibited in a concentration-dependent manner by ritonavir and nelfinavir but not by indinavir. Ritonavir and nelfinavir lowered [Ca2+]c in the presence of a stimulatory glucose concentration whereas indinavir again had no effect. Ritonavir and nelfinavir completely inhibited the effect of tolbutamide, which normally increases [Ca2+]c by blocking KATP channels. This observation points to an action of both drugs on KATP channels or a step distal to these channels in stimulus-secretion coupling. Ritonavir was used to further evaluate the direct effects of HIV protease inhibitors on beta-cell ion channel currents. Unexpectedly, ritonavir inhibited neither the whole-cell KATP current nor the whole-cell L-type Ca2+ current. Tolbutamide almost completely suppressed the KATP current in the presence of ritonavir excluding that ritonavir alters the tolbutamide sensitivity of the KATP channel. Ritonavir increased the length and decreased the frequency of glucose-induced action potentials. This effect can be attributed to inhibition of voltage-dependent K+ currents. Intracellular stores seem not to be involved in the ritonavir-induced lowering of [Ca2+]c. In conclusion, different HIV protease inhibitors surprisingly reveal distinct effects on insulin secretion. Ritonavir inhibits insulin secretion by lowering [Ca2+]c but this effect is evidently independent of the opening of KATP channels or the closure of voltage-dependent Ca2+ channels, which are commonly considered to play a key role in stimulus-secretion coupling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197535     DOI: 10.1007/s00210-004-0933-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  Editorial comment on Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.

Authors:  C Merry
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

2.  Role of voltage- and Ca2(+)-dependent K+ channels in the control of glucose-induced electrical activity in pancreatic B-cells.

Authors:  J C Henquin
Journal:  Pflugers Arch       Date:  1990-07       Impact factor: 3.657

3.  The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

Authors:  H Murata; P W Hruz; M Mueckler
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

4.  Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.

Authors:  J F Denissen; B A Grabowski; M K Johnson; A M Buko; D J Kempf; S B Thomas; B W Surber
Journal:  Drug Metab Dispos       Date:  1997-04       Impact factor: 3.922

5.  Indinavir induces acute and reversible peripheral insulin resistance in rats.

Authors:  Paul W Hruz; Haruhiko Murata; Haijun Qiu; Mike Mueckler
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

6.  Insulin resistance in HIV protease inhibitor-associated diabetes.

Authors:  K E Yarasheski; P Tebas; C Sigmund; S Dagogo-Jack; A Bohrer; J Turk; P A Halban; P E Cryer; W G Powderly
Journal:  J Acquir Immune Defic Syndr       Date:  1999-07-01       Impact factor: 3.731

7.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

8.  Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues.

Authors:  A Rudich; D Konrad; D Török; R Ben-Romano; C Huang; W Niu; R R Garg; N Wijesekara; R J Germinario; P J Bilan; A Klip
Journal:  Diabetologia       Date:  2003-04-24       Impact factor: 10.122

Review 9.  Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets.

Authors:  P E MacDonald; M B Wheeler
Journal:  Diabetologia       Date:  2003-06-27       Impact factor: 10.122

10.  Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells.

Authors:  G Trube; P Rorsman; T Ohno-Shosaku
Journal:  Pflugers Arch       Date:  1986-11       Impact factor: 3.657

View more
  11 in total

1.  Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Madhu N Rao; Grace A Lee; Carl Grunfeld
Journal:  Am J Infect Dis       Date:  2006-09-30

Review 2.  The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Authors:  Grace A Lee; Madhu N Rao; Carl Grunfeld
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

Review 3.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

4.  Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Authors:  Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 5.  Current understanding of HIV-associated neurocognitive disorders pathogenesis.

Authors:  Patrick Gannon; Muhammad Z Khan; Dennis L Kolson
Journal:  Curr Opin Neurol       Date:  2011-06       Impact factor: 5.710

6.  HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation.

Authors:  Patrick J Gannon; Cagla Akay-Espinoza; Alan C Yee; Lisa A Briand; Michelle A Erickson; Benjamin B Gelman; Yan Gao; Norman J Haughey; M Christine Zink; Janice E Clements; Nicholas S Kim; Gabriel Van De Walle; Brigid K Jensen; Robert Vassar; R Christopher Pierce; Alexander J Gill; Dennis L Kolson; J Alan Diehl; Joseph L Mankowski; Kelly L Jordan-Sciutto
Journal:  Am J Pathol       Date:  2017-01       Impact factor: 4.307

7.  The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.

Authors:  Grace A Lee; Madhu N Rao; Carl Grunfeld
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

Review 8.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

9.  HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.

Authors:  Paul W Hruz
Journal:  Curr Opin HIV AIDS       Date:  2008-11       Impact factor: 4.283

10.  Nelfinavir inhibits intra-mitochondrial calcium influx and protects brain against hypoxic-ischemic injury in neonatal mice.

Authors:  Irina V Utkina-Sosunova; Zoya V Niatsetskaya; Sergey A Sosunov; Veniamin I Ratner; Dzmitry Matsiukevich; Vadim S Ten
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.